Endometriosis Market Insights, Epidemiology and Market Forecast-2028

Albany, NY -- (SBWire) -- 10/15/2019 --Endometriosis Market Insights, Epidemiology and Market Forecast-2028

1. Endometriosis total prevalent population in the 7 major markets ranges from 2,611,800 in 2017
2. In 2017, there were 7,457,600 Endometriosis prevalent cases in the United States.
3. Japan accounts for the second-highest Endometriosis prevalent cases. In 2017, there were 2,611,830 prevalent cases of Endometriosis in Japan.

(Albany, US) DelveInsight launched a new report on Endometriosis Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Endometriosis market report covers a descriptive overview and comprehensive insight of the Endometriosis epidemiology and Endometriosis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Endometriosis market report provides insights on the current and emerging therapies.
3. Endometriosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Endometriosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Endometriosis market.

Request for sample pages

"There were 2,486,310 diagnosed Endometriosis prevalent cases in the 7MM."

The therapeutic Endometriosis market in 7MM was found to be USD 1067.63 Million in 2017, which is expected to increase during the study period 2017-2028. Endometriosis is a chronic pelvic disease in which the menstrual blood that is supposed to flow out through the vagina travels up through the fallopian tubes and accumulates around the ovaries. There is currently no cure for the condition. Treatment is based upon whether the primary complaint is pain or infertility and duration of the disease. There are many options to manage and treat endometriosis including a healthy lifestyle, pain-relief medications, and hormone therapy such as the oral contraceptive pill, progestin, and surgery.
Standard medical therapies for patients with endometriosis include analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs] or acetaminophen), oral contraceptive pills (OCPs), androgenic agents (e.g.,danazol [Danocrine]), progestogens (e.g., medroxyprogesterone acetate [Provera]), gonadotropin-releasing hormone analogues (GnRHas; e.g., leuprolide [Lupron], goserelin [Zoladex], triptorelin [Trelstar Depot], nafarelin [Synarel]), and antiprogestogens (e.g., gestrinone).
In 2018, the US Food and Drug Administration (FDA) approved Orilissa (Elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate-to-severe endometriosis pain. Orilissa represents the first FDA-approved oral treatment for the management of moderate-to-severe pain associated with endometriosis in over a decade.
Apart from the above-mentioned therapeutic medications, different types of surgeries, including laparoscopy, laparotomy, and hysterectomy, are also performed. Surgery is often recommended to remove the tissue, which relieves the symptoms for a while. Birth control pills are often prescribed to slow down the growth of abnormal tissue, and nonsteroidal anti-inflammatory drugs such as ibuprofen help ease the pain.
Overall, the increasing diagnosed prevalence of the disease along with the promising emerging pipeline therapies is expected to fuel the Endometriosis market size during the forecasted period of 2019-2028.

The launch of the emerging therapies is expected to significantly impact the Endometriosis treatment scenario in the upcoming years:-
Drugs covered
1. Decapeptyl
2. OBE2109
3. FOR-6219
4. Vilaprisan
5. Relugolix
And many others

The key players in Endometriosis market are:
1. Ipsen Pharmaceuticals
2. ObsEva SA
3. Forendo pharma ltd
4. Bayer
5. Ferring Pharmaceuticals
6. Myovant Sciences
And many others

Table of contents

1. Key Insights
2. Endometriosis Market Overview at a Glance
3. Endometriosis Disease Background and Overview
4. Endometriosis Epidemiology and Patient Population
5. Country Wise-Epidemiology of Endometriosis
6. United States
7. EU-5
7.1. Assumptions and Rationale
7.2. Germany
7.3. France
7.4. Italy
7.5. Spain
7.6. United Kingdom
8. Japan
9. Endometriosis Treatment
10. Endometriosis Current Treatment Practices
11. Endometriosis Treatment Guidelines
12. Unmet Needs
13. Endometriosis Marketed Drugs
13.1. Lupron (leuprolide acetate depot)
13.2. Depo-SubQ Provera 104
13.3. Visanne
13.4. Zoladex
13.5. Synarel (nafarelin nasal spray)
13.6. Pamorelin/Decapeptyl/Trelstar
13.7. Elagolix
14. Endometriosis Emerging Therapies
14.1. FOR-6219: Forendo pharma
14.2. Relugolix: Myovant Sciences GmbH
14.3. OBE2109: ObsEva SA
15. Endometriosis 7 Major Market Analysis
16. Market Outlook by Country
17. The United States: Market Outlook
17.1. United States Market Size
18. EU-5 Countries: Market Outlook
18.1.1. Germany Market Size
18.1.2. France Market Size
18.1.3. Italy Market Size
18.1.4. Spain Market Size
18.1.5. The United Kingdom Market Size
19. Japan: Market Outlook
20. Market Drivers
21. Market Barriers
22. Appendix
23. Sources Used
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight